We would like to thank Armoiry et al1 for investing the time and effort to further advance our research.We carefully considered their solution to our assumption regarding the equal relative effectiveness of bortezomib (Bor) versus dexamethasone (Dex) and bortezomib plus dexamethasone (BorDex) versus Dex. [...]

Additional Metadata
Sponsor Supported by Grant No. 152001020 from ZonMw, the Netherlands Organisation for Health Research and Development.
Persistent URL dx.doi.org/10.1200/JCO.2017.73.7569, hdl.handle.net/1765/101935
Journal Journal of Clinical Oncology
Citation
van Beurden-Tan, C.H.Y, Franken, M.G, Blommestein, H.M, Uyl-de Groot, C.A, & Sonneveld, P. (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35(25), 2976–2977. doi:10.1200/JCO.2017.73.7569